



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyyssw@sina.com

产品名称: (R) - CR8

CAS 号: 294646-77-8

产品货号: S87699

生物活性:

Description	(R)-CR8 是 Roscovitine 的第二代类似物, 是一种有效的 CDK1/2/5/7/9 抑制剂。(R)-CR8 抑制 CDK1/cyclin B (IC ₅₀ =0.09 μM)、CDK2/cyclin A (0.072 μM)、CDK2/cyclin E (0.041 μM)、CDK5/p25 (0.11 μM)、CDK7/cyclin H (1.1 μM)、CDK9/cyclin T (0.18 μM) 和 CK1 δ/ε (0.4 μM)。(R)-CR8 诱导细胞凋亡并具有神经保护作用。(R)-CR8 作为一种分子胶降解剂来消耗细胞周期蛋白 K。						
IC ₅₀ & Target[1]	Cdk1/cyclin B 0.09 μM (IC ₅₀)	cdk2/cyclin A 0.072 μM (IC ₅₀)	CDK2/cyclin E 0.041 μM (IC ₅₀)	Cdk5/p25 0.11 μM (IC ₅₀)	CDK7/cyclin H 1.1 μM (IC ₅₀)	CDK9/Cyclin T 0.18 μM (IC ₅₀)	CK1δ/ε 0.4 μM (IC ₅₀)
Cellular Effect	Cell Line	Type	Value	Description			
	G-361	IC ₅₀	0.503 μM	Cytotoxicity against human G361 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay			
	HCT-116	IC ₅₀	0.35 μM	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay			
	HEK293	IC ₅₀	0.56 μM	Antiproliferative activity against HEK293 cells assessed as survival after 48 hrs by MTS reduction assay			
	HT	GI ₅₀	0.263 μM	Antiproliferative activity against human HT cells measured after 72 hrs by calcein AM dye-based fluorescence assay			
	K562	IC ₅₀	0.175 μM	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay			
	MCF7	IC ₅₀	0.16 μM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by calcein AM staining based fluorescence assay			
	Sf9	IC ₅₀	0.062 μM	Inhibition of His-tagged CDK2/Cyclin-E1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured in presence of [gamma-33P]ATP			
	Sf9	IC ₅₀	0.062 μM	Inhibition of CDK2/Cyclin E (unknown origin) expressed in sf9 cells using histone H1 as substrate in presence of [gamma33P]-ATP			
	Sf9	IC ₅₀	0.225 μM	Inhibition of recombinant human full-length N-terminal GST-His6-fused CDK5 (M1 to P292 residues)/N-terminal His6-tagged p25 (A104 to R307 residues) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured in presence of [gamma-33P]ATP			
	Sf9	IC ₅₀	0.272 μM	Inhibition of recombinant human N-terminal GST-His6-fused CDK2 (M1 to F372 residues)/N-terminal His6-tagged cyclin T1 (M1 to K372 residues) expressed in baculovirus infected Sf9 insect cells using (YSPTSPS)2KK as substrate measured in presence of [gamma-33P]ATP			
	Sf9	IC ₅₀	0.787 μM	Inhibition of His-tagged CDK1/Cyclin-B1 (unknown origin) expressed in baculovirus infected Sf9 insect cells using histone H1 as substrate measured in presence of [gamma-33P]ATP			
	Sf9	IC ₅₀	1.769 μM	Inhibition of recombinant human N-terminal GST-His6-fused CDK1			



				(M1 to F346 residues)/N-terminal His-tagged cyclin H (M1 to L32 residues)/N-terminal His6-tagged MAT1 (M1 to S306 residues) expressed in baculovirus infected Sf9 insect cells using (YSPTSPS		
	Sf9	IC ₅₀	26.09 μM	Inhibition of recombinant human N-terminal GST-fused CDK4 (S E303 residues)/cyclin D1 (Q4 to I295 residues) expressed in baculovirus infected Sf9 insect cells using RPPTLSPIPHIPR as substrate measured in presence of [gamma-33P]ATP		
	SH-SY5Y	IC ₅₀	0.43 μM	Antiproliferative activity against human SH-SY5Y cells assessed a survival after 48 hrs by MTS reduction assay		
In Vitro	(R)-CR8 (CR8) (0.1-100 μM; 48 小时) 是细胞凋亡的强效诱导剂, 对 SH-SY5Y 细胞系的 IC ₅₀ 为 0.49 μM[1]。					
	(R)-CR8 (0.25-10 μM) 诱导剂量依赖性的聚-(ADP-核糖)聚合酶 (PARP) 裂解[1]。					
	(R)-CR8 的 CDK 结合形式具有溶剂暴露的吡啶基部分, 可诱导 CDK12-细胞周期蛋白 K 与 CUL4 衔接蛋白 DDB1 之间形成复合物, 从而无需底物受体并呈递细胞周期蛋白 K 进行泛素化和降解[3]。					
	Apoptosis Analysis[1]					
	Cell Line:		SH-SY5Y cell line			
	Concentration:		0.1, 1, 10, 100 μM			
In Vivo	Incubation Time:		24 hours			
	Result:		Reduced cell survival in a dose-dependent manner.			
	(R)-CR8 (5 mg/Kg; 腹腔注射) 在 28 天的组织学评估中导致病变大小显著减小[2]。					
	Animal Model:		Adult (10 to 12 weeks old) male Sprague-Dawley rats (310 to 330 g)[2]			
	Dosage:		i.p.			
	Administration:		5 mg/Kg			
Solvent&Solubility	Result:		Resulted in a significant reduction in lesion size.			
	细胞实验:					
	DMSO 中的溶解度 : 50 mg/mL (115.87 mM; 超声助溶 (<60° C); 吸湿的 DMSO 对产品的溶解度有显著影响, 请使用新开封的 DMSO)					
	Preparing Stock Solutions	Solvent Concentration Mass	1 mg	5 mg	10 mg	
			1 mM	2.3173 mL	11.5867 mL	23.1734 mL
			5 mM	0.4635 mL	2.3173 mL	4.6347 mL
10 mM			0.2317 mL	1.1587 mL	2.3173 mL	
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。						
储备液的保存方式和期限: -80°C, 6 months; -20°C, 1 month。-80°C 储存时, 请在 6 个月内使用, -20°C 储存时, 请在 1 个月内使用。						
参考文献	[1]. Bettayeb K, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807.					
	[2]. Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13.					
	[3]. Slabicki M, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K					



[published online ahead of print, 2020 Jun 3]. Nature. 2020;10.1038/s41586-020-2374-x.

完整储备液配制表:

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。

储备液的保存方式和期限: -80° C, 6 months; -20° C, 1 month。 -80° C 储存时,请在 6 个月内使用, -20° C 储存时,请在 1 个月内使用。

可选溶剂	质量 溶剂体积 浓度	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3173 mL	11.5867 mL	23.1734 mL	57.9334 mL
	5 mM	0.4635 mL	2.3173 mL	4.6347 mL	11.5867 mL
	10 mM	0.2317 mL	1.1587 mL	2.3173 mL	5.7933 mL
	15 mM	0.1545 mL	0.7724 mL	1.5449 mL	3.8622 mL
	20 mM	0.1159 mL	0.5793 mL	1.1587 mL	2.8967 mL
	25 mM	0.0927 mL	0.4635 mL	0.9269 mL	2.3173 mL
	30 mM	0.0772 mL	0.3862 mL	0.7724 mL	1.9311 mL
	40 mM	0.0579 mL	0.2897 mL	0.5793 mL	1.4483 mL
	50 mM	0.0463 mL	0.2317 mL	0.4635 mL	1.1587 mL
	60 mM	0.0386 mL	0.1931 mL	0.3862 mL	0.9656 mL
	80 mM	0.0290 mL	0.1448 mL	0.2897 mL	0.7242 mL
	100 mM	0.0232 mL	0.1159 mL	0.2317 mL	0.5793 mL